Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bioniche Life Sciences Inc.
ClinicalTrials.gov Identifier:
NCT00406068
First received: December 1, 2006
Last updated: August 28, 2014
Last verified: August 2014

December 1, 2006
August 28, 2014
November 2006
July 2011   (final data collection date for primary outcome measure)
One year disease-free survival rate [ Time Frame: Prospective ] [ Designated as safety issue: No ]
One year disease-free survival rate
Complete list of historical versions of study NCT00406068 on ClinicalTrials.gov Archive Site
  • The 3, 6 and 24 month disease-free survival rate [ Time Frame: Prospective ] [ Designated as safety issue: No ]
  • Duration of disease-free survival in all patients [ Time Frame: Prospective ] [ Designated as safety issue: No ]
  • Time to progression to muscle invasive disease [ Time Frame: Prospective ] [ Designated as safety issue: No ]
  • Overall survival in all patients [ Time Frame: Prospective ] [ Designated as safety issue: No ]
  • Rate of overall drug-related adverse events leading to two consecutive treatment delays of one week each or to the discontinuation of treatment. [ Time Frame: Prospective ] [ Designated as safety issue: Yes ]
  • The 3, 6 and 24 month disease-free survival rate
  • Duration of disease-free survival in all patients
  • Time to progression to muscle invasive disease
  • Overall survival in all patients
  • Rate of overall drug-related adverse events leading to two consecutive treatment delays of one week each or to the discontinuation of treatment.
Not Provided
Not Provided
 
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG

The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in situ) of the urinary bladder at high risk of progression who are refractory to therapy with bacillus Calmette-Guerin (BCG).

The study will be divided into 3 phases: Induction, Maintenance, and Follow-up.

The Induction Phase will cover a period of 6 weeks. During this time, patients will receive 6 weekly intravesical instillations of 8 mg MCC. The patients will be evaluated at month 3, at which time the patients will enter the Maintenance Phase. The Maintenance Phase will last from month 3 to month 24, and during this time, patients will receive weekly MCC instillations for three weeks at months 3, 6, 12, 18, and 24 and evaluations will be performed at months 3, 6, 9, 12, 15, 18, 21 and 24.

At month 3, the patient will be evaluated to assure that the disease is not progressing. Cytology, cystoscopy and biopsies will be performed to obtain adequate staging (if residual tumor persists). If the patient is disease-free, maintenance therapy will be initiated. Patients with non-muscle invasive tumors at month 3 will, at the discretion of the investigator, receive either a second 6-week induction course or a 3-week maintenance course. Patients who show progression to muscle invasive disease will be referred to other treatments.

At month 6 and thereafter at each evaluation visit, patients will be evaluated and managed according to the following results:

  • Patients who are disease-free will continue on maintenance treatment.
  • Patients who are not disease-free (evidence of papillary lesions, CIS or muscle invasive disease) will be withdrawn from further study treatment and will be referred to other therapies at the discretion of the investigator.

The final 36 months of the study is the Follow-up Phase. Evaluations will be performed at months 30, 36, 42, 48, 54 and 60.

Efficacy evaluations will include standard cystoscopy, biopsies and urine cytology. During the Maintenance Phase, standard cystoscopies will be performed at months 3, 6, 9, 12, 15, 18, 21 and 24 for the surveillance of bladder tumors. During the months that instillations will be performed, cystoscopies will be conducted only once at each of these months. During the Follow-up Phase, cystoscopies will be performed at months 30, 36, 42, 48, 54 and 60.

Mandatory bladder biopsies will be done for all patients at month 6.

During the course of the study, biopsies will be taken only if evident or suspicious lesions are seen during cystoscopy or in case of negative cystoscopy but positive cytology.

Interventional
Phase 2
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bladder Neoplasms
Drug: Mycobacterial cell wall-DNA complex
8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Other Name: MCC - Urocidin
Experimental: Mycobacterial cell wall-DNA complex
Mycobacterial cell wall-DNA complex
Intervention: Drug: Mycobacterial cell wall-DNA complex
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
129
July 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients refractory to BCG therapy;
  • Patients with histologically confirmed diagnosis of high grade lesions;
  • Diagnosis of high grade lesion must be within 56 days prior to beginning of study treatment;
  • Have had all visible papillary lesion(s) resected by TURBT within 56 days prior to beginning of study treatment;
  • Available for the whole duration of the study including follow-up (60 months);
  • Life expectancy of > 5 years;
  • Patients with an ECOG performance status grade of 2 or less;
  • Absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra within 12 months from beginning of study treatment;
  • Able to understand and give written informed consent;
  • In the investigator's judgment, the patient is able to participate in the study.

Exclusion Criteria:

  • Current or previous history of muscle invasive tumors;
  • Current or previous history of lymph node or distant metastases from bladder cancer;
  • Current systemic cancer therapy;
  • Current or prior pelvic external beam radiotherapy;
  • Pelvic brachytherapy within 2 years of study entry;
  • Prior treatment with MCC;
  • Patients with existing urinary tract infection or recurrent severe bacterial cystitis;
  • Clinically significant and unexplained elevations of liver or renal function tests;
  • White blood cell count below 3 x109/L (3,000/mm3) or platelet count below 100 x 109/L(100,000/mm3);
  • Severe cardiovascular disease;
  • Women who are pregnant or lactating;
  • Congenital or acquired immune deficiency;
  • With history of malignancy of any organ system, treated or untreated, within the past 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, stage T1 prostate cancer, carcinoma in situ of the cervix or colon polyps);
  • Previous investigational treatment within 3 months from beginning of study treatment;
  • Patients who cannot hold the instillation for one hour;
  • Patients who cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy);
  • Clinically significant active infections;
  • Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
NCT00406068
HIS-0611-0602
Yes
Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc.
Not Provided
Principal Investigator: Alvaro Morales, MD Centre for Applied Urological Research, Kingston General Hospital/Queen's University
Bioniche Life Sciences Inc.
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP